The effect of losartan potassium on choroidal hemodynamics in healthy subjects.
OBJECTIVE
To investigate the choroidal hemodynamic effects of losartan potassium, a specific angiotensin II subtype AT1 receptor antagonist.


METHODS
In this prospective, randomized, observer-masked, open-label placebo-controlled (lactose), two-period crossover study, the choroidal hemodynamic effects of a single oral 50-mg dose of losartan potassium were evaluated in 12 healthy subjects using choroidal laser Doppler flowmetry.


RESULTS
Perfusion pressure and the choroidal laser Doppler flowmetry parameters velocity, volume, and flux did not vary significantly compared with placebo (P = 0.33, 0.31, 0.74, and 0.61, respectively). Correcting choroidal laser Doppler flowmetry parameters for perfusion pressure in a covariance analysis did not change these results.


CONCLUSIONS
A single oral 50-mg dose of the angiotensin II AT1 receptor antagonist losartan potassium given does not disturb the homeostasis of ocular perfusion pressure or choroidal blood flow in young healthy subjects.
University Eye Clinic, Basel, Switzerland.
Tatiana
T
Spicher
Selim
S
Orgül
Konstantin
K
Gugleta
Barbara
B
Teuchner
Josef
J
Flammer
D000284:Administration, Oral; D000328:Adult; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001783:Blood Flow Velocity / Q000187:drug effects; D002829:Choroid / Q000098:blood supply*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D017078:Laser-Doppler Flowmetry; D019808:Losartan / Q000494:pharmacology*; D008297:Male; D010477:Perfusion; D011446:Prospective Studies; D044140:Receptor, Angiotensin, Type 1; D012039:Regional Blood Flow / Q000187:drug effects; D014792:Visual Acuity / Q000187:drug effects
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D044140:Receptor, Angiotensin, Type 1; D019808:Losartan